Prophylactic therapy with Fibrogammin® P is associated with a decreased incidence of bleeding episodes: a retrospective study
Authors:
- 25 February 2010
- journal article
- case report
- Published by Wiley in Haemophilia
- Vol. 16 (2) , 316-321
Abstract
Summary. Congenital factor XIII (FXIII) deficiency is an extremely rare, yet potentially life‐threatening, bleeding disorder, with a 30% rate of spontaneous intracranial haemorrhage. Routine prophylactic management is recommended for all individuals with clinically relevant (FXIII) deficiency and for all symptomatic individuals with congenital factor deficiency. Fibrogammin® P is a purified, pasteurized concentrate of FXIII that appears to carry negligible risk of viral transmission, unlike other unprocessed products containing FXIII. An ongoing Phase II/III study of Fibrogammin® P in patients with congenital FXIII deficiency is being conducted to evaluate the prophylactic efficacy and long‐term safety of this product. Using retrospective chart review data from subjects enrolled in the Phase II/III study, the current analysis was designed to compare spontaneous bleed‐event rates prior to and after the initiation of Fibrogammin® P prophylaxis. Seven subjects were evaluable for comparison, having received no other prophylactic FXIII‐containing product during the 24 months prior to study entry. The mean annual number of spontaneous bleeds was 2.5 events per year prior to Fibrogammin® P prophylaxis and 0.2 events per year during Fibrogammin® P prophylaxis (P = 0.01). Patients reported no severe bleeds during Fibrogammin® P therapy. This small sample supports a consistent and clinically meaningful reduction in spontaneous bleeding with prophylactic use of Fibrogammin® P.Keywords
This publication has 10 references indexed in Scilit:
- International Registry on Factor XIII Deficiency: A basis formed mostly on European dataThrombosis and Haemostasis, 2007
- Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiencyBlood, 2006
- Characterisation of six novel A-subunit mutations leading to congenital factor XIII deficiency and molecular analysis of the first diagnosed patient with this rare bleeding disorderThrombosis and Haemostasis, 2006
- Prophylaxis in rare coagulation disorders — Factor XIII deficiencyThrombosis Research, 2006
- Clinico-Hematologic Profile of Factor XIII-Deficient PatientsClinical and Applied Thrombosis/Hemostasis, 2005
- The rare coagulation disorders – review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' OrganisationHaemophilia, 2004
- Delayed Umbilical Bleeding—A Presenting Feature for Factor XIII Deficiency: Clinical Features, Genetics, and ManagementPediatrics, 2002
- Two novel and one recurrent missense mutation in the factor XIII A gene in two Dutch patients with factor XIII deficiencyBritish Journal of Haematology, 2001
- ETRO Working Party on Factor XIII Questionnaire on Congenital Factor XIII Deficiency in Europe: Status and PerspectivesSeminars in Thrombosis and Hemostasis, 1996
- A Hitherto Undescribed Congenital Haemorrhagic Diathesis Probably Due to Fibrin Stabilizing Factor DeficiencyThrombosis and Haemostasis, 1961